[A23-03] Olaparib (prostate cancer) - Benefit assessment according to § 35a SGB V

Last updated 06.07.2023

Project no.:

Commission awarded on 16.01.2023 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adults with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated

Result of dossier assessment:
  • Patients with treatment-naive mCRPC < 65 years: hint of minor added benefit
  • Patients with treatment-naive mCRPC ≥ 65 years: hint of lesser benefit
  • Patients with pretreated mCRPC: added benefit not proven

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Federal Joint Committee (G-BA)

2023-07-06 A G-BA decision was published.

G-BA documents on this decision


Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.


Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form